Accuray Incorporated (ARAY)
After hours:
| Previous Close | 2.1200 |
| Open | 2.1600 |
| Bid | 2.1600 x 300 |
| Ask | 2.2000 x 900 |
| Day's Range | 2.1200 - 2.2050 |
| 52 Week Range | 1.4000 - 3.1000 |
| Volume | |
| Avg. Volume | 867,280 |
| Market Cap | 217.345M |
| Beta (5Y Monthly) | 1.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Gifu Prefectural General Medical Center Achieves Milestone with Treatment of the First Cancer Patients in Japan Using the Accuray Radixact® System and VitalHold™ Solution
Accuray Incorporated (NASDAQ: ARAY) announced today that Gifu Prefectural General Medical Center is setting a new standard in cancer care in Japan as the first hospital in the country to treat patients with surface-guided radiation therapy (SGRT) using the company's Radixact® Radiation Delivery System and VitalHold™* package. SGRT is designed to help medical care teams to effectively position the patient and confidently monitor the accuracy of that positioning throughout treatment. The ability t
- PR Newswire
Accuray President and Chief Executive Officer Suzanne Winter to Take Temporary Medical Leave of Absence
Accuray Incorporated (NASDAQ: ARAY) announced today that President and Chief Executive Officer Suzanne Winter will be taking a temporary medical leave of absence to receive care for a treatable form of cancer, effective immediately. Accuray Senior Vice President and Chief Commercial Officer Sandeep Chalke will serve as the interim CEO during Ms. Winter's absence. To ensure that Mr. Chalke and the organization have the necessary support, the company has formed an Executive Committee of the Board
- PR Newswire
Accuray Receives CE Mark for a New Helical Radiation Delivery System, Accuray Helix™
Accuray Incorporated (NASDAQ: ARAY) announced today the company has received CE Mark for Accuray Helix™, a CT-guided helical radiotherapy system designed to provide high-performance and high-throughput. The new system is intended for emerging markets where access to advanced cancer care, including radiotherapy treatments, is typically obtainable only within urban areas and where the availability of linear accelerators per million population is well below the World Health Organization recommended
